Literature

Home
Company Info
- Management Team
- Bor-Wen Wu, PhD MBA
- John Bomalaski, MD
- Archie Prestayko, PhD
- Amanda Johnston, PhD
- W. Jenny Kung, PhD
- Wei He, PhD
- Jim Thomson, PhD
- Steve Wu
- Advisory Board
- Lloyd J. Old, MD
- George Demetri, MD
- Robert C. Jackson, PhD
- Hsing-Jien Kung, MD PhD
- Jedd D. Wolchok, MD PhD
- Subsidiaries
- Polaris Pharmaceuticals
- TDW Pharmaceuticals
- DRX Pharmaceuticals
- DRX (Shanghai)
Pipeline
Collaborations
Literature
- Polaris & Collaborators
- ADI-PEG 20 (oncology)
- Uricase-PEG 20:
- TNF-PEG 20:
- CK2 inhibitor:
- ADI-PEG 20 (antiviral):
- Related Publications
- ADI general:
- ADI (oncology) renal cell carcinoma:
- ADI (oncology) combination therapy:
- TNF cancer treatment:
- CK2 inhibitor:
- Histidase cancer treatment:
Company News
Contact

ADI-PEG 20 (oncology)

Reduced Argininosuccinate Synthetase Is a Predictive Biomarker for the Development of Pulmonary Metastasis in Patients with Osteosarcoma

E. Kobayashi, M. Masuda, R. Nakayama, H. Ichikawa, R. Satow, M. Shitashige, K. Honda, U. Yamaguchi, A. Shoji, N. Tochigi, H. Morioka, Y. Toyama, S. Hirohashi, A. Kawai, T. Yamada
Molecular Cancer Therapeutics (2010), Vol. 9 pages 535-44